Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio. Find out why I give AMGN stock a ...

Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in sales. CEO Robert Bradway emphasized the company's resilience in navigating challenges like ...

In his 13 years as CEO at Amgen, Robert Bradway has seen many of his counterparts at other major biopharma companies come and ...

Repatha alone contributed a 40% sales increase ... Looking forward, Amgen maintains its 2024 revenue guidance between $33 billion and $33.8 billion, with a non-GAAP EPS range of $19.20 to $ ...

As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for the unusually large number of drugs affected. Among the companies facing ...

Nearly a year after winning an accelerated approval for its DLL3-targeting small cell lung cancer (SCLC) therapy Imdelltra, ...